Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEOLUS dupilumab imaging study in COPD
2025-521268-37-00Phase 4Authorised
- Sponsor
- Sanofi
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Dupixent with Matched placebo (2 arms). Primary endpoint: Change from baseline to Week 24 in global lung mucus score. Planned start Nov 2025; status: authorised.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-521268-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521268-37-00.